Related Experiment Video
Updated: Feb 3, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Ligustrazine inhibits platelet activation via suppression of the Akt pathway
Li Li1, Hongwei Chen1, Aling Shen1
1Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China.
Insights
Ligustrazine hydrochloride inhibits platelet activation by suppressing the Akt signaling pathway, offering potential cardiovascular benefits without increasing bleeding risk. This study clarifies the antiplatelet mechanisms of this traditional Chinese medicine component.
Area of Science:
- Pharmacology
- Cardiovascular Research
- Molecular Biology
Background:
- Aberrant platelet activation is central to thrombotic vascular events like atherosclerosis and myocardial infarction.
- The phosphoinositide 3-kinase/AKT serine/threonine kinase (Akt) pathway plays a key role in platelet activation.
- Rhizoma Ligusticum Wallichii (RLW), a traditional Chinese herb, is used for cardiovascular disorders, with ligustrazine being its active component.
Purpose of the Study:
- To evaluate the effects of ligustrazine hydrochloride (LH) on platelet activation.
- To investigate the underlying molecular mechanisms of ligustrazine's antiplatelet activity.
- To determine if Akt signaling suppression mediates ligustrazine's bioactivities.
Main Methods:
- In vitro and ex vivo platelet activation models using rat platelet-rich plasma.
- Stimulation with adenosine diphosphate (ADP) or insulin-like growth factor-1 (IGF-1).
- Measurement of platelet aggregation, thromboxane A2 (TXA2) secretion, intracellular Ca2+ mobilization, and Akt phosphorylation.
Main Results:
- LH dose-dependently inhibited ADP-induced platelet aggregation, TXA2 secretion, and Ca2+ mobilization.
- LH suppressed both ADP- and IGF-1-induced Akt phosphorylation.
- LH inhibited IGF-1-induced platelet aggregation, TXA2 formation, and Ca2+ mobilization, and reversed adrenaline-induced shortening of bleeding time.
Conclusions:
- Ligustrazine exhibits broad-spectrum antiplatelet activities with no apparent hemorrhagic side effects.
- Suppression of the Akt signaling pathway is a key mechanism underlying ligustrazine's antiplatelet effects.
- Ligustrazine holds potential for managing thrombotic vascular events.
Abstract:
Aberrant activation of platelets has a critical role in thrombotic vascular events, including atherosclerosis, arterial thrombosis and myocardial infarction. The process of platelet activation is associated with multiple intracellular signaling pathways, including the phosphoinositide 3‑kinase/AKT serine/threonine kinase (Akt) pathway. The well‑known medicinal herb Rhizoma Ligusticum Wallichii (RLW) has long been used in China to clinically treat various cardiovascular disorders. As the most pharmacologically active component of RLW, ligustrazine has been demonstrated to possess a potent antiplatelet activity. However, the precise mechanisms mediating the bioactivities of ligustrazine have not been thoroughly elucidated. The present study evaluated the effects of ligustrazine hydrochloride (LH; the clinical‑grade form of ligustrazine) on platelet activation and investigated the underlying molecular mechanisms. In vitro and ex vivo platelet activation models were used, established by stimulating rat platelet‑rich plasma either with the platelet activator adenosine diphosphate (ADP) or with the specific Akt pathway activator insulin‑like growth factor‑1 (IGF‑1). The results demonstrated that treatment with LH significantly and dose‑dependently inhibited ADP‑induced platelet aggregation, in addition to thromboxane A2 (TXA2) secretion and intracellular Ca2+ mobilization in platelets, in vitro and ex vivo. In addition, LH markedly suppressed ADP‑induced Akt phosphorylation in vitro and ex vivo. Furthermore, LH markedly inhibited IGF‑1‑induced Akt phosphorylation, platelet aggregation, TXA2 formation and Ca2+ mobilization in vitro. Finally, LH was able to reverse adrenaline‑induced shortening of bleeding time. Taken together, these results suggested that ligustrazine possesses a broad range of antiplatelet activities without apparent hemorrhagic side-effects, and suppression of Akt signaling may be one of the mechanisms by which ligustrazine exerts its antiplatelet activities.
More Related Videos
04:37Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
05:49Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Inhibition of Cdk Activity
Feedback Inhibition
Prokaryotic Transcriptional Activators and Repressors
Transcription of prokaryotic...
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Enzyme Inhibition